The change of name is a contractual requirement of its divestment from TTP Group in 2018 with the backing of technology-focused investment firm Battery Ventures
Problem: Advancements in technology in the scientific arena have led to the requirement to store larger numbers of compounds including small molecules, potential drug candidates or biological samples.
Since the early 1990s, biobanking has been evolving as a key resource, increasing the availability and use of biological material such as DNA, RNA, tissues and cells for biomedical research.
It is essential for medicinal chemists to have access to analytical instrumentation for reaction monitoring and product analysis. However, due to the associated high capital cost and maintenance overheads, it is not possible to install and support instrumentation in every lab across a research site.
We’ve updated our Privacy Policy to make it clearer how we use your personal data.
Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.